The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of HER3 targeted antibody patritumab in combination with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
 
Toshiaki Saeki
No Relationships to Disclose
 
Hirofumi Mukai
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; Nippon Kayaku; Novartis; Pfizer; Sanofi
 
Kenjiro Aogi
Honoraria - AstraZeneca; Becton Dickinson; Chugai Pharma; Daiichi Sankyo; Eisai; Nihon Medi-Physics; Ono Pharmaceutical; Otsuka; Sanofi; Taiho Pharmaceutical
 
Takashi Shigekawa
No Relationships to Disclose
 
Shigeto Ueda
No Relationships to Disclose
 
Yoichi Naito
Honoraria - Daiichi Sankyo
 
Nobuaki Matsubara
No Relationships to Disclose
 
Seiki Takashima
No Relationships to Disclose
 
Fumikata Hara
Research Funding - Chugai Pharma; Eisai
 
Tomonari Yamashita
Employment - Daiichi Sankyo
 
Shoichi Ohwada
Employment - Daiichi Sankyo
 
Yasutsuna Sasaki
Honoraria - Chugai Pharma; Eisai; Merck Serono; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Taiho Pharmaceutical